MedPath

The efficacy of H. pylori eradication therapy with sitafloxacin-metronidazole-vonaprazan regime

Not Applicable
Recruiting
Conditions
Helicobacter pylori infection
A498
Registration Number
JPRN-jRCTs031180412
Lead Sponsor
Hirata Kenro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

H. pylori-positve patients after the 2nd line H. pylori eradication therapy or penicillin-allergic patients

Exclusion Criteria

1. Patients with allergy for quinolones
2. Patients with allergy for PPIs
3. Patients with severe liver injury and/or severe renal damage
4. Pregnancy or possible pregnancy
5. Patients who were recognized as inappropriate for entry

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The efficacy of eradication treatment
Secondary Outcome Measures
NameTimeMethod
1) adverse events <br>2) MIC of STFX,MNZ, gyrA mutation
© Copyright 2025. All Rights Reserved by MedPath